Lilly to invest over $1.2 billion to expand Puerto Rico facility
The enhanced facility will be among those that will manufacture for orforglipron, Lilly’s first oral, small-molecule GLP-1 receptor agonist.
The enhanced facility will be among those that will manufacture for orforglipron, Lilly’s first oral, small-molecule GLP-1 receptor agonist.
Eli Lilly announced its Team USA lineup for the 2026 Winter Games. The company will also expand its Milestones into Meaning program.
“Moderate-to-severe obstructive sleep apnea is more than just snoring – it’s a serious condition and it deserves serious attention,” O’Neal said.
The acquisition strengthens Lilly’s genetic medicine pipeline and expands its footprint in ophthalmology.
Lilly’s oral GLP-1 pill helped patients lose 22 pounds and lower A1C in a Phase 3 trial, with global filings planned this year.
Will include a planned investment up to a $250 million to accelerate pharmaceutical innovation.
Eli Lilly and Company enhances digital healthcare offerings to address delays in diagnosis and treatment.